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POSTIRANSPLANT Iymphoproliferative disorder (PTLD) is a weU-recognized complication after trans-
plantation. and has been reported to occur in approxi-
mately 2% of organ transplant recipients both with cyclo-
sporine and FK 506 immunosuppression. f~ The use of FK 
506 in clinical small bowel transplantation has resulted in 
improved patient and graft survival.7 This report describes 
the clinical and pathologic features of PTLD occurring in 
intestinal transplant recipients treated primarily with FK 
506. This complication has been known to be a special risk 
of intestinal transplantation since the first reports of long 
survival of multivisceral recipients who were treated with 
cyclosporine.8 •9 
MATERIALS AND METHODS 
Case Material 
Between May 2. 1990 and August 7. 199354 patients received 
intestinal transplants with or without other abdominal organs 
using FK 506 as their primary immunosuppressive therapy. This 
group comprised 18 isolated intestine recipients (I), 26 Iiverl 
intestine recipients (UI), and 10 multivisceral recipients (MV) (\ 
MV without the liver or modified multivisceraJ). Within this 
population 29 pediatric patients were transplanted. including 5 I. 
20 UI. and 4 MV recipients. 
Immunosuppressive therapy (induction. and treatment of rejec-
tion) was as previously described and based on FK 506 as primary 
drug. 7 
Pathologic Studies 
All available surgical and autopsy specimens as well as Epstein-
Barr virus (EBV) serologic data were reviewed. The evaluation of 
PTLD lesions included histopathology, analysis of clonal status, 
and demonstration of EBV (by in situ hybridization for EBERl. 
RESULTS 
Patient Population and Tumor Incidence 
Eight cases of PTLD were identified. Four occurred in 
males and 4 occurred in females (M:F ratio, 1/11. The age 
of these recipients at the time of transplantation ranged 
from 1.7 to 44 years. Six patients were children. with a 
mean age of 4. I years. The time between the date of organ 
transplant and the date of disease presentation ranged 
between 24 days and 2.3 years: however. 6 patients 
presented after 10 months posttransplant (mean of 1.2 
years). These l:! cases represent 14.l:!% of the total study 
population. rhe overall incidence in adult recipients was 
S%. and the overolll incidence in pediatric recipients was 
20.6<:{-. The distnbution of cases relative to the graft type 
revealed 5 cases in LlI grafts. and 3 cases in M V grafts. 
Interestingly. the 2 adult patients were recipients of MY 
grafts. 
Clinical Presentation and Location of PTLO 
Symptoms of fever. weight loss, and malaise were com-
mon (4 patients), although nonspecific, initiating a work-up 
and a search for infection and/or rejection. One patient 
presented with hemolysis and diarrhea. A Iymphadeno-
pathic presentation was noted in 2 patients (22%) and 
localized to the head and neck region in I patient and 
generalized in the other. Six patients (66.6%) had involve-
ment of the gastrointestinal tract presenting as nodular 
ulcerated tumors. The intestinal graft was involved with 
disease in 5 patients (55.5%) and generally presented with 
vomiting, diarrhea. and gastrointestinal bleeding. Of these. 
2 patients developed complications related to their graft 
that included bleeding and intestinal perforation. One 
patient presented isolated right lung involvement. After 
resolution of this tumor she later presented spindle ceU 
tumors in the native colon that were positive for EBV at in 
situ hybridization studies. One patient presented fulminant 
disseminated disease. a recipient of an MV graft who 
received intensive therapy for early exfoliative type rejec-
tion of the intestine. He developed early onset disease 
(involving all thoracic and abdominal organs) and died of 
fulminant PTLD and multisystem organ failure at 2 months 
posttransplant. Of note, PTLD was identified on routine 
endoscopy without associated symptoms in 2 patients. 
PathologiC Features of PTLD 
The evaluation of PTLD in this series was hindered by 
sample size and necrosis (when ulcers were present). The 
range of histology was that of activated lymphocytes with 
a polymorphic appearance, which was seen in all patients. 
Clonal analysis was feasible in only 4 cases: the lesions 
were monoclonal in all cases studied. Evidence of EBV 
DNA was found in all specimens. 
Serologic evidence of EBV infection was found in all 
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patients. 7 were· non primary infections. and was pri-
mary. 
Treatment 
Treatment consisted of reduction of immunosuppression 
combined with intravenous acyclovir or gancyclovir for as 
long as there were lesions present. Alpha interferon and/or 
Foscarnet were used in selected cases where there seemed 
to be rapid progression of disease. extensive disease. 
recurrent disease. or there had been a history of severe 
rejection and immunosuppression could not be reduced. In 
2 cases the immunosuppression was stopped entirely while 
there was evidence of clinical disease. In I patient immu-
nosuppression was not reduced because of previous repet-
itive rejections. This patient had resolution of lesions on 
gancyc10vir and alpha interferon. Lesions were followed 
by a combination of endoscopy. and radiologic studies 
(computed tomographic scans. plain and contrast films. 
etc). 
Outcome 
Five of the 8 patients diagnosed with PTLD have survived 
(mortality of 37.5%) with a mean follow-up of 20 months. 
Four of these surviving patients have had complete remis-
sion of their disease. whereas I patient continues to have 
lesions and is under therapy. Four surviving patients have 
retained their grafts. All of these patients are presently on 
maintenance immunosuppression using FK 506. Four pa-
tients developed rejection after resolution of their PTLD 
and required aggressive therapy. Three patients were 
treated successfully with resumption of maintenance FK 
506 therapy and steroids; I patient was retransplanted. 
The deaths in this series of PTLD occurred in recipients 
of Ul(n = 2) and MV (n = I) grafts. The median time from 
transplant to death as a result of PTLD was 15 months. Of 
these 3 patients who died all were identified as having 
residual PTLD at autopsy. Two fatalities (66%) presented 
severe bacterial and fungal infection as well as multisystem 
organ failure. One of these patients presented perforation 
and bleeding of the PTLD lesions. Two of these patients 
who died had received OKT3 some time during their 
course. One patient died of iatrogenic administration of an 
excessive amount of enteral sodium after successful treat-
ment of PTLD. He was found to have recurrent PTLD at 
autopsy. 
DISCUSSION 
Three identifiable factors could contribute to the higher 
incidence of PTLD (14.8lJt:) in these intestinal transplant 
recipients: the lymphoid content of (he graft. the aggres-
sive immunotherapy required in these cases. and earlier 
diagnosis in 2 patients in whom the EBV was identified by 
in situ hybridization. One patient who was at the lower end 
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of the EBV infection spectrum before clonal expansion 
and tumor development was diagnosed after presentation 
with minimal enlargement of cervical lymph node and 
flulike symptoms. Hopefully. early diagnosis will improve 
treatment response. 
The time of PTLD onset in these intestinal recipients 
was later (> 10 months I than in recipients of other kinds of 
organ transplants. U However. there were 3 examples of 
early aggressive disease. from which 2 patients died. The 
spectrum of lesions was peculiar in that histologically the 
PTLDs were all within the range of a polymorphic pattern. 
Also. monoclonality was found in the 4 patients studied. 
2 patients with severe disease and 2 patients with a 
mononucleosis-like picture. The occurrence of spindle cell 
lesions in 2 patients reflects a significant. as of yet un-
explained. deviation from the expected pattern. Complica-
tions of PTLD (infections. bleeding, perforation) and late 
diagnosis have been responsible for death in 2 patients. 
Gastrointestinal involvement. of both native and trans-
planted gut. was the most common site of presentation. A 
Iymphodenopathic presentation is amenable to a rapid and 
complete remission of their disease. with preservation of 
graft function. 
The mainstay of therapy is above all reduction of 
immunosuppression to which i~travenous acyclovir or 
gancyclovir is an adjuvant measure. The risk of complete 
discontinuation of treatment is rejection. which led to 
retransplantation in I patient and left another child with a 
marginal graft. PTLD was treated successfully in I child 
while maintaining base line immunosuppression. 
The role of alpha interferon and foscarnet for the 
treatment of any PTLD in organ transplant recipients 
remains to be determined. These agents may be regarded 
as adjuvant to reduction of immunosuppression in patients 
with severe disease. or as primary treatment in selected 
patients for whom reduction of immunosuppression would 
carry a high risk of rejection. 
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